Original Articles

You have full text access to this OnlineOpen article

Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients

  1. Nicola J. Goodson1,
  2. Nicola J. Wiles1,
  3. Mark Lunt1,
  4. Elizabeth M. Barrett2,
  5. Alan J. Silman1,
  6. Deborah P. M. Symmons1,*

Article first published online: 9 AUG 2002

DOI: 10.1002/art.10419

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 8, pages 2010–2019, August 2002

Additional Information

How to Cite

Goodson, N. J., Wiles, N. J., Lunt, M., Barrett, E. M., Silman, A. J. and Symmons, D. P. M. (2002), Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis & Rheumatism, 46: 2010–2019. doi: 10.1002/art.10419

Author Information

  1. 1

    ARC Epidemiology Unit, University of Manchester Medical School, Manchester, UK

  2. 2

    Norfolk Arthritis Register, St. Michael's Hospital, Aylsham, Norfolk, UK

*ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK

Publication History

  1. Issue published online: 9 AUG 2002
  2. Article first published online: 9 AUG 2002
  3. Manuscript Accepted: 2 APR 2002
  4. Manuscript Received: 11 JUN 2001

Funded by

  • Arthritis Research Campaign, UK

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

REFERENCES

  • 1
    Wolfe F, Mitchell DM, Sibley JT, Fries JF. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94.
    Direct Link:
  • 2
    Wållberg-Jonsson S, Öhman ML, Rantapää-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997; 24: 445–51.
  • 3
    Van Schaardenburg D, Hazes J, de Boer A, Zwinderman AH, Meijers KAE, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993; 20: 45–52.
  • 4
    Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcomes in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072–7.
  • 5
    Reilly P, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year study of 100 patients. Ann Rheum Dis 1990; 49: 363–9.
  • 6
    Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92–9.
  • 7
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864–72.
    Direct Link:
  • 8
    Myllykangas-Luosujärvi R, Aho K, Kautianen H, Isomäki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22: 1065–7.
  • 9
    Mitchell DW, Spitz P, Young D, Bloch D, McShane D, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706–14.
    Direct Link:
  • 10
    Linos A, Worthington JW, O'Fallon W, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence and mortality. Am J Epidemiol 1980; 111: 87–98.
  • 11
    Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999; 58: 11–4.
  • 12
    Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29–37.
  • 13
    Kroot EJA, van Leeuwen MA, van Rijswijk MH, Prevoo MLL, van 't Hof MA, van de Putte LBA, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000; 59: 954–8.
  • 14
    Erhardt CC, Mumford PA, Venables PJW, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7–13.
  • 15
    Allebeck P, Ahlbom A, Allander E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Scand J Rheumatol 1981; 10: 301–6.
  • 16
    Kullo I, Gau G, Tajik A. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369–80.
  • 17
    Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124–6.
  • 18
    Symmons DPM, Barrett EM, Bankhead CR, Scott DGI, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735–9.
  • 19
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 20
    Wiles N, Symmons DPM, Harrison B, Barrett E, Barrett JH, Scott DGI, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999; 42: 1339–46.
    Direct Link:
  • 21
    Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25: 206–9.
  • 22
    International classification of diseases, ninth revision. Geneva: World Health Organization; 1977.
  • 23
    Cox DR. Regression models and life tables (with discussions). J R Stat Soc 1972; 34: 187–220.
  • 24
    Hosmer DWJ, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
  • 25
    Statistical package for the social sciences: version 9.0. Chicago: SPSS; 1999.
  • 26
    Stata Statistical Software: release 6.0. College Station (TX): Stata Corporation; 1999.
  • 27
    Heliövaara M, Aho K, Knekt P, Aromaa A, Maatela J, Reunanen A. Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis 1995; 45: 811–4.
  • 28
    Koenig W, Sund M, Frolich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg study 1984 to 1992. Circulation 1999; 99: 237–42.
  • 29
    Kuller L, Tracy R, Shaten J, Meilahn E. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Am J Epidemiol 1996; 144: 537–47.
  • 30
    Ridker PM, Hennikens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43.
  • 31
    Ridker PM, Cushman M, Stampher MJ, Tracy RP, Hennikens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
  • 32
    Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis. Ann Intern Med 1993; 118: 956–63.
  • 33
    Situnayake RD, Kitas G. Dyslipidaemia and rheumatoid arthritis. Ann Rheum Dis 1997; 56: 341–2.
  • 34
    Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennikens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 28: 1817–21.
  • 35
    Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997; 40: 718–22.
    Direct Link:
  • 36
    Morgan SL, Baggott JE, Lee JY, Alarcón GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease. J Rheumatol 1998; 25: 441–6.
  • 37
    Haagsma CJ, Blom HJ, van Riel PLCM, van 't Hof MA, Giesendorf BAJ, van de Putte LBA, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79–84.
  • 38
    Wållberg-Jonsson S, Johansson H, Rantapää-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562–71.
  • 39
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–9.
  • 40
    Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27: 630–7.
  • 41
    Del Rincon I, Williams K, Stern MP, Escalante A. High Incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S385.
  • 42
    Cisternas M, Gutierrez MA, Klassen J, Acosta AM, Jacobelli S. Risk factors for cardiovascular disease in Chilean patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S153.
  • 43
    Braunwald E. Cardiovascular Medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997; 337: 1360–9.
View Full Article (HTML) Get PDF (75K)